Secondary Diffuse Choroid Plexus B-Cell Lymphoma: Case Report and Review of Literature

被引:1
作者
Chen, Bi Yi [1 ]
Chen, Vivien [1 ]
Inam, Shafqat [1 ]
Yin, Charlotte [2 ]
Damodaran, Omprakash [1 ]
机构
[1] Concord Gen Repatriat Hosp, Concord, Australia
[2] Royal North Shore Hosp, St Leonards, NSW, Australia
关键词
Chemotherapy; Intraventricular lymphoma; Secondary central nervous system lymphoma; CENTRAL-NERVOUS-SYSTEM; PRIMARY CNS LYMPHOMA; NON-HODGKINS-LYMPHOMA; INTRAVENOUS METHOTREXATE; RITUXIMAB; PROPHYLAXIS; INVOLVEMENT; RECURRENCE; DIAGNOSIS; TRIAL;
D O I
10.1016/j.wneu.2019.04.203
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND: Central nervous system (CNS) relapse is an uncommon complication of diffuse large B cell lymphoma and is associated with significant mortality and morbidity. It is becoming a more prevalent pathologic entity in the rituximab era. Our case provides insight into the pathophysiology, diagnosis, prevention, and management of secondary intraventricular CNS lymphomas. CASE DESCRIPTION: We report an unusual case of a 64-year-old man who presented with an isolated secondary CNS lymphoma involving the choroid plexus in a diffuse pattern. He initially presented with obstructive hydrocephalus from diffuse choroid plexus lesions and was commenced on systemic therapy after confirmation of diagnosis via samples obtained from an open biopsy. CONCLUSIONS: This case highlights the lack of high-quality evidence behind the use of high-dose intravenous methotrexate as CNS prophylaxis. The case provides additional insight into the pathophysiology of intraventricular CNS lymphomas and the importance of establishing a histopathologic diagnosis via an open biopsy before the administration of high-dose steroids.
引用
收藏
页码:18 / 22
页数:5
相关论文
共 26 条
[1]   Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk Patients With Diffuse Large B-Cell Lymphoma [J].
Abramson, Jeremy S. ;
Hellmann, Matthew ;
Barnes, Jeffrey A. ;
Hammerman, Peter ;
Toomey, Christiana ;
Takvorian, Tak ;
Muzikansky, Alona ;
Hochberg, Ephraim P. .
CANCER, 2010, 116 (18) :4283-4290
[2]   The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma [J].
Arkenau, H. -T. ;
Chong, G. ;
Cunningham, D. ;
Watkins, D. ;
Agarwal, R. ;
Sirohi, B. ;
Trumper, M. ;
Norman, A. ;
Wotherspoon, A. ;
Horwich, A. .
ANNALS OF ONCOLOGY, 2007, 18 (03) :541-545
[3]   CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) [J].
Boehme, Volkmar ;
Schmitz, Norbert ;
Zeynalova, Samira ;
Loeffler, Markus ;
Pfreundschuh, Michael .
BLOOD, 2009, 113 (17) :3896-3902
[4]   Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation - an International Primary Central Nervous System Lymphoma Study Group project [J].
Bromberg, Jacoline E. ;
Doorduijn, Jeanette K. ;
Illerhaus, Gerald ;
Jahnke, Kristoph ;
Korfel, Agniezka ;
Fischer, Lars ;
Fritsch, Kristina ;
Kuittinen, Outti ;
Issa, Samar ;
van Montfort, Cees ;
van den Bent, Martin J. .
HAEMATOLOGICA, 2013, 98 (05) :808-813
[5]   Primary CNS Lymphoma in Immunocompetent Patients [J].
del Rio, Monica Sierra ;
Rousseau, Audrey ;
Soussain, Carole ;
Ricard, Damien ;
Hoang-Xuan, Khe .
ONCOLOGIST, 2009, 14 (05) :526-539
[6]   Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era? [J].
Deng, Lijuan ;
Song, Yuqin ;
Zhu, Jun ;
Zheng, Wen ;
Wang, Xiaopei ;
Xie, Yan ;
Lin, Ningjing ;
Tu, Meifeng ;
Ping, Lingyan ;
Ying, Zhitao ;
Liu, Weiping ;
Zhang, Chen .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (06) :664-671
[7]   Isolated Recurrence of Secondary CNS Lymphoma: Case Report and Literature Review [J].
DeRosa, Peter ;
Cappuzzo, Justin M. ;
Sherman, Jonathan H. .
JOURNAL OF NEUROLOGICAL SURGERY REPORTS, 2014, 75 (01) :E154-E159
[8]   Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial [J].
Ferreri, Andres J. M. ;
Cwynarski, Kate ;
Pulczynski, Elko ;
Ponzoni, Mourilio ;
Deckert, Martina ;
Politi, Letterio S. ;
Torri, Valter ;
Fox, Christopher P. ;
La Rosee, Paul ;
Schorb, Elisabeth ;
Ambrosetti, Achille ;
Roth, Alexander ;
Hemmoway, Claire ;
Ferrari, Angela ;
Linton, Kim M. ;
Ruda, Roberta ;
Binder, Mascha ;
Pukrop, Tobias ;
Balzarotti, Monica ;
Fabbri, Alberto ;
Johnson, Peter ;
Gorlov, Jette Sonderskov ;
Hess, Georg ;
Panse, Jens ;
Pisani, Francesco ;
Tucci, Alessandra ;
Stilgenbauer, Stephan ;
Hertenstein, Bernd ;
Keller, Ulrich ;
Krause, Stefan W. ;
Levis, Alessandro ;
Schmoll, Hans J. ;
Covalli, Franco ;
Finke, Jurgen ;
Reni, Michele ;
Zucca, Emanuele ;
Illerhaus, Gerald .
LANCET HAEMATOLOGY, 2016, 3 (05) :E217-E227
[9]   High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? [J].
Glantz, MJ ;
Cole, BF ;
Recht, L ;
Akerley, W ;
Mills, P ;
Saris, S ;
Hochberg, F ;
Calabresi, P ;
Egorin, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1561-1567
[10]  
HERMAN TS, 1979, CANCER-AM CANCER SOC, V43, P390, DOI 10.1002/1097-0142(197901)43:1<390::AID-CNCR2820430155>3.0.CO